Immune Pharmaceuticals Initiates Phase II Clinical Trial In Ulcerative Colitis
Week ending April 27: Quarterly earnings continue to boost market's spirits.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...
Three ways to separate long-term winners from stocks that fizzle.